Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

Study Overview
=================
Brief Summary
-----------------
Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Detailed Description
-----------------
Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Official Title
-----------------
Clinical Observation of CHD Phlegm and Blood-stasis Syndrome Patients

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy or metabolism syndrome people Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure Exclusion Criteria: Any inflammation, fever, trauma, burn or operation within 1 week Obstructive pulmonary disease Cerebral vascular disease Severe renal or hepatic dysfunction Malignant neoplasms Hematopoietic system disease Sever mental disease

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>the healthy patients | |
| Metabolic syndrome group<br>Include patients who are accordance with diagnostic criteria of metabolic syndrome | |
| CHD stable stage group<br>Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome | |
| Acute coronary syndrome group<br>Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction | |
| PCI or CABG group<br>Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting | |
| CHD heart failure group<br>Include the patients who suffered heart failure cause by CHD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 6 months |